Tech Company Financing Transactions

Flare Therapeutics Funding Round

On 3/22/2023, Flare Therapeutics raised $123 million in Series B funding from GordonMD Global Investments, Pfizer Venture Investments and Agent Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

215 First St 150
Cambridge, MA 02142
USA

Phone

(857) 706-4400

Website

www.flaretx.com

Email Address

[email protected]

Overview

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare's team is leveraging the power of 'switch sites' as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target 'switch sites' has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Amit Rakhit

        

Chief Operating Officer

Daphne Karydas

        

Chief Scientific Officer

Robert Sims

        

Vice President

Jim Audia

        

Browse more venture capital transactions:

Prev: 3/22/2023: Appbrew venture capital transaction
Next: 3/22/2023: IPRally Technologies venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary